Oxurion NV (OXUR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oxurion NV (OXUR) has a cash flow conversion efficiency ratio of 0.097x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.16 Million ≈ $-1.36 Million USD) by net assets (€-11.99 Million ≈ $-14.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See OXUR cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Oxurion NV - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Oxurion NV's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Oxurion NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oxurion NV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rajvir Industries Limited
NSE:RAJVIR
|
-0.158x |
|
FIH Group PLC
LSE:FIH
|
-0.067x |
|
Guess? Inc.
NYSE:GES
|
-0.070x |
|
Montfort Capital Corp
V:MONT
|
-2.810x |
|
Windar Photonics Plc
LSE:WPHO
|
-0.022x |
|
GETT Gold Inc
V:GETT
|
-0.004x |
|
PT Sreeya Sewu Indonesia Tbk
JK:SIPD
|
-0.047x |
|
Eden Research plc
LSE:EDEN
|
-0.048x |
Annual Cash Flow Conversion Efficiency for Oxurion NV (2006–2024)
The table below shows the annual cash flow conversion efficiency of Oxurion NV from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see OXUR market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-11.06 Million ≈ $-12.93 Million |
€-2.07 Million ≈ $-2.42 Million |
0.187x | -74.75% |
| 2023-12-31 | €-13.19 Million ≈ $-15.42 Million |
€-9.77 Million ≈ $-11.42 Million |
0.741x | -83.04% |
| 2022-12-31 | €-4.58 Million ≈ $-5.36 Million |
€-20.02 Million ≈ $-23.40 Million |
4.367x | -82.18% |
| 2021-12-31 | €-1.11 Million ≈ $-1.30 Million |
€-27.16 Million ≈ $-31.75 Million |
24.508x | +2365.49% |
| 2020-12-31 | €25.05 Million ≈ $29.28 Million |
€-27.10 Million ≈ $-31.68 Million |
-1.082x | -85.42% |
| 2019-12-31 | €53.31 Million ≈ $62.32 Million |
€-31.10 Million ≈ $-36.36 Million |
-0.583x | -97.46% |
| 2018-12-31 | €105.31 Million ≈ $123.12 Million |
€-31.12 Million ≈ $-36.38 Million |
-0.295x | -249.85% |
| 2017-12-31 | €133.36 Million ≈ $155.91 Million |
€26.30 Million ≈ $30.74 Million |
0.197x | +206.66% |
| 2016-12-31 | €109.86 Million ≈ $128.44 Million |
€-20.31 Million ≈ $-23.74 Million |
-0.185x | -13.08% |
| 2015-12-31 | €170.01 Million ≈ $198.77 Million |
€-27.79 Million ≈ $-32.49 Million |
-0.163x | +27.00% |
| 2014-12-31 | €208.01 Million ≈ $243.19 Million |
€-46.58 Million ≈ $-54.46 Million |
-0.224x | -325.38% |
| 2013-12-31 | €258.77 Million ≈ $302.53 Million |
€25.71 Million ≈ $30.06 Million |
0.099x | -18.50% |
| 2012-12-31 | €227.97 Million ≈ $266.52 Million |
€27.79 Million ≈ $32.49 Million |
0.122x | +173.54% |
| 2011-12-31 | €118.03 Million ≈ $137.99 Million |
€-19.56 Million ≈ $-22.87 Million |
-0.166x | -36.00% |
| 2010-12-31 | €138.19 Million ≈ $161.56 Million |
€-16.84 Million ≈ $-19.69 Million |
-0.122x | +5.59% |
| 2009-12-31 | €93.72 Million ≈ $109.57 Million |
€-12.10 Million ≈ $-14.14 Million |
-0.129x | -167.36% |
| 2008-12-31 | €62.39 Million ≈ $72.94 Million |
€11.96 Million ≈ $13.98 Million |
0.192x | +162.73% |
| 2007-12-31 | €48.44 Million ≈ $56.63 Million |
€-14.80 Million ≈ $-17.30 Million |
-0.306x | -28.03% |
| 2006-12-31 | €35.28 Million ≈ $41.24 Million |
€-8.42 Million ≈ $-9.84 Million |
-0.239x | -- |
About Oxurion NV
Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness in Belgium. The company is developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991… Read more